Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportPoster - Technologist

Lutetium-177: a flexible radionuclide therapeutic options

Madhusudan Vyas
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 3039;
Madhusudan Vyas
1Unitec Institute of Technology West Auckland New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

3039

Objectives: 1. Understand the evolving theranostic applications of a promising radionuclide Lutetium-177. 2. Review and highlight the role of Lutetium-177 in improving the quality of life for patients affected with Neuroendocrine tumour (NET) and metastatic castration-resistant prostate cancer (mCRPC).

Background: A'theranostic 'term is used when the same agent may be used to combine two interdependent applications, namely diagnosis and treatment. Iodine-131 is the most widely used radionuclide that falls into the concept of ideal Theranostics. Lutetium is a late entrant, but it is emerging as a game-changer for the treatment of NET over a short period of time and shows useful results for the treatment of mCRPC. Due to simultaneous imageable gamma photon and particulate emission, less penetrable to healthy cells, lutetium is commonly used as an option in radionuclide therapy. In addition, the long half-life of simple chemistry makes it a natural ligand for different therapeutic agents. It is simple to manage because of the amount of permissible emission of beta and gamma radiation from Lutetium. Finding and procedure detail Various clinical studies performed under the NETTER (Neuroendocrine Tumors Therapy Study) and the latest continuing trial for the treatment of mCRPC have been reviewed. These studies showed that Lutetium-177 was an effective agent in the affected patients to boost the quality of life and progression-free survival. The role of Lutetium-177-labeled Rituximab in the treatment of Herceptin-defined breast cancer was also reviewed by one party.

Conclusions: Lutetium-177 has shown to be very useful in treating numerous types of tumours. The results of several clinical studies promise Lutetium-177 as a flexible theranostic agent an exciting and great potential for the future.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lutetium-177: a flexible radionuclide therapeutic options
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Lutetium-177: a flexible radionuclide therapeutic options
Madhusudan Vyas
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 3039;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lutetium-177: a flexible radionuclide therapeutic options
Madhusudan Vyas
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 3039;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster - Technologist

  • Optimization of Standardized Uptake Value of Fluorodeoxyglucose for Cortical Extraction in dedicated brain PET System
  • Utilization of Gallium-68 Dotatate PET MRI for the Evaluation of Meningioma in a Major Tertiary Academic University Neurosurgical Center
  • Artificial Intelligence in Nuclear Medicine for Brain Imaging.
Show more Poster - Technologist

Technologist Poster Session

  • Optimization of Standardized Uptake Value of Fluorodeoxyglucose for Cortical Extraction in dedicated brain PET System
  • Utilization of Gallium-68 Dotatate PET MRI for the Evaluation of Meningioma in a Major Tertiary Academic University Neurosurgical Center
  • Artificial Intelligence in Nuclear Medicine for Brain Imaging.
Show more Technologist Poster Session

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire